The methylation of MGMT promotor is correlated with a better disease outcome [4], while the status of IDH is the basis for GBM’s classification into three subgroups: IDH-mutant, wild-type IDH, and “not otherwise specified” (NOS) [10,11]. This evidence concerns the gene IDH1 and glioblastoma.